FDA Staff: Mediocre Efficacy for Merck's Pill in High-Risk COVID
Full analysis pours cold water on molnupiravir's initially promising findings
Source: medpagetoday.com
Stay updated with breaking news from Molly Walker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Full analysis pours cold water on molnupiravir's initially promising findings
Characterized as 'red flag,' but questions remain about immune escape, transmissibility
Maribavir (Livtencity) okayed for patients ages 12 and up, with or without genotypic resistance
French study found low neutralizing antibody titers, little immune response
Pilot study suggests alternative to insecticides for vector control